Thermo Fisher Scientific, Inc., BD, Agilent Technologies, Inc. dominated the Asia-Pacific Flow Cytometry Market in 2022

Asia-Pacific Flow Cytometry Market is expected to grow with a CAGR of 10.6% in the forecast period of 2022 to 2029. The years considered for the study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/asia-pacific-flow-cytometry-market

The Asia-Pacific flow cytometry market is a highly consolidated market. The market has witnessed increased strategic developments owing to favorable market scenarios.

The major players in the Asia-Pacific flow cytometry market are introducing a strong range of product portfolios. This helped companies to maximize sales with an enhanced product portfolio.

For instance,

• In November 2019, Thermo Fisher Scientific Inc. acquired MTI-GlobalStem, a private company that develops and commercializes leading-edge technology and reagents for cell transfection, neurobiology, and stem cell research applications. This helps the company in enhancing its stem cell research market

Thermo Fisher Scientific Inc. is expected to dominate the Asia-Pacific flow cytometry market. Some of the other players are Sysmex Asia Pacific Pte Ltd, Agilent Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Luminex Corporation., Sony Biotechnology Inc., Apogee Flow Asia Ltd., Cytek Biosciences, bioMérieux SA, Merck KGaA, Elabscience Biotechnology Inc., Miltenyi Biotec, Takara Bio Inc., Q2 Solutions., CellKraft Biotech Pvt. Ltd., Sartorius AG, NeoGenomics Laboratories., Bay bioscience Co., Ltd., Cell Signaling Technology, Inc., CytoBuoy b.v., ORFLO Technologies., IKEDA SCIENTIFIC Co., Ltd., BioLegend, Inc., II-VI Incorporated, among others.

Thermo Fisher Scientific, Inc.

Thermo Fisher Scientific, Inc. was founded in 2006 and is headquartered in Massachusetts, U.S. It has public ownership. The company focuses on making the world healthier, cleaner, and safer by accelerating life science research, solving complex analytical challenges, and improving patients' therapies and diagnostics. The company has business segments such as life science solutions, analytical instruments, specialty diagnostics, laboratory products, and services. Amongst this, the market-focused segment is life science solutions. The company offers a range of product categories, including life sciences, industrial & applied sciences, clinical diagnostics, lab solutions, and digital solutions. Amongst which the market-focused category is life sciences.

• In December 2020, Thermo Fisher Scientific Inc. acquired Phitonex, Inc., a private company that develops and commercializes high-resolution biology applications to accelerate research and development in cell therapy, immuno-oncology, and immunology research. This acquisition will expand flow cytometry and imaging multiplexing in protein and cell analysis research

The company has a global presence in North America, Europe, Asia-Pacific, the Middle East and Africa. The company has many subsidiaries, such as Thermo Electron North America LLC (U.S.), Fisher Scientific GmbH (Germany), Fisher Scientific Korea Ltd (Korea), Thermo Fisher Scientific Germany BV & Co KG (Germany), Thermo Fisher Scientific K.K. (Japan), among others.

BD

BD was founded in 1897 and is headquartered in New Jersey, U.S. It has public ownership. The company focuses on innovation by accelerating life science research, solving complex analytical challenges, and improving patient therapies and diagnostics. The company has business segments such as BD Medical, BD Life Sciences, and BD Interventional. Amongst which BD Life Sciences is the market-focused segment. The company offers a range of product categories such as medication delivery solutions, medication management solutions, diabetes care, pharmaceutical system, integrated diagnostic solutions, preanalytical system, diagnostic system, surgery, peripheral intervention, and urology & critical care. Amongst which the market-focused category is integrated diagnostic solutions.

• In July 2021, BD introduced a new online portal, an e-commerce site for online purchasing that Reimagined Digital Marketplace for Flow Cytometry by 24/7 order tracking for purchasing resources. This helps in expanding the research and clinical innovation market

The company has a global presence in North America, South America, Europe, the Middle East and Africa, Asia-Pacific. The company has many subsidiaries such as Accuri Cytometers (Europe),Ltd., Atto Bioscience,Inc. (U.K), BD (U.K)Ltd, Becton Dickinson Matrex Holdings, Inc (U.K), BD Norge AS (EU), among others.

Agilent Technologies, Inc.

Agilent Technologies, Inc. was founded in 1999 and is headquartered in California, U.S. It has public ownership. The company focuses on providing laboratory solutions through better scientific and business results by accelerating research, solving complex analytical challenges, and improving patients' therapies and diagnostics. The company provides business segments such as Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. Amongst which the market-focused segment is Life Sciences and Applied Markets.

The company offers product categories including Analytical Instruments & Supplies, Life Science, Clinical & Diagnostic Testing, Lab Management & Consulting, Lab Software, and Lab supplies. Amongst which the market-focused category is clinical & diagnostic testing.

• In March 2021, Agilent Technologies Ltd. acquired Resolution Biosciences (U.S), a leader in oncology solutions. This acquisition helped the company in expanding oncology diagnostics by accelerating research, solving complex analytical challenges, and improving patients therapies

The company has a global presence in the Americas, Europe, Asia-Pacific. The company has many subsidiaries such as Agilent Technologies Canada Inc.(North America); Agilent Technologies (U.K), Agilent Technologies Ireland Limited (EU), Agilent Technologies Italia S.p.A, among others.